Abstract
Objectives To identify COVID-19 outbreaks and border control failures associated with quarantine systems in Australia and New Zealand and to estimate the failure risks.
Design, setting, participants Observational epidemiological study of travellers transiting quarantine in Australia and New Zealand up to 15 June 2021.
Main outcome measures The incidence of COVID-19 related failures arising from quarantine, and the failure risk for those transiting quarantine, estimated both per 100,000 travellers and per 1000 SARS-CoV-2 positive cases.
Results Australia and New Zealand had 32 COVID-19 related failures arising from quarantine systems up to 15 June 2021 (22 and 10, respectively). One resultant outbreak involved an estimated 800 deaths and quarantine failures instigated nine lockdowns. The failure risk for those transiting quarantine was estimated at 5.0 failures per 100,000 travellers and 6.1 failures (95%CI: 4.0 to 8.3) per 1000 SARS-CoV-2 positive cases. The latter risk was two-fold higher in New Zealand compared with Australia. The full vaccination of frontline border workers could likely have prevented a number of quarantine system failures.
Conclusions Quarantine system failures can be costly in terms of lives and economic impacts such as lockdowns. Ongoing improvements or alternatives to hotel-based quarantine are required.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Prof Baker and Dr Kvalsvig received funding support from the Health Research Council of New Zealand (20/1066). Dr Grout, Ms Katar, Dr Ait Ouakrim, Dr Summers, Prof Blakely, and Prof Wilson did not have external funding support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
There was no requirement for ethics review as the study only utilised publicly available anonymised data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The data in this manuscript have been updated through 15 June 2021. Some of the text has been revised to reflect updated estimates. We have deleted some information that is now out-of-date, including Appendix Table 2.
Data Availability
The datasets analyzed during the current study were derived from public resources available from the New Zealand Ministry of Business Innovation & Employment, the New Zealand Ministry of Health. the Australia Bureau of Statistics. and the Australian Department of Health.
https://www.health.gov.au/resources/collections/coronavirus-covid-19-common-operating-picture
